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Patients with unresectable metastatic colorectal cancer live for a median of three years when treated with
standard therapies. While the evidence guiding cancer-directed treatment of this disease comes from phase III
trials that have mostly enrolled patients with good performance status, some patients present with poor clinical
conditions. The best treatment for these patients remains to be determined. We performed a systematic review
of the treatment outcomes of patients with metastatic colorectal cancer and poor performance status, defined
as Eastern Cooperative Oncology Group performance status X2. Eligible articles were prospective or retro-
spective studies or case reports published in English, Portuguese or Spanish. We searched PubMed, EMBASE,
LILACS and the Cochrane Library from onset until October 2017 using specific keywords for each search.
We found a total of 18 publications, mostly case reports and retrospective studies (14 articles). One was an
uncontrolled prospective trial, two were observational studies and one was an individual patient meta-analysis.
Although some studies suggested benefits in terms of symptomatic response with standard chemotherapy, with
good safety profiles when dose-reduced regimens were administered, a true survival gain could not be demon-
strated. The scientific evidence for treating metastatic colorectal cancer patients with poor performance status
is scarce, and more studies evaluating treatment for this population are necessary since this condition is not
uncommon in clinical practice, particularly in the public healthcare system and developing countries and among
destitute populations.
KEYWORDS: Metastatic Colorectal Cancer; Poor Performance; Chemotherapy; Performance; Survival.
’ INTRODUCTION
Nearly 50% of patients with colorectal cancer have meta-
static or nonoperable disease at the time of diagnosis or
will develop metastasis or a local recurrence in the following
months to years (1). For patients with unresectable metastatic
disease, the prognosis is bleak, with 5-year survival rates of
5% or less (2). Chemotherapy prolongs progression-free sur-
vival (PFS) and overall survival (OS) compared with best
supportive care (BSC) alone (3) or polychemotherapy, specifi-
cally with FOLFOX (leucovorin + 5-fluorouracil (5-FU) +
oxaliplatin) and FOLFIRI (leucovorin + 5-FU + irinotecan)
regimens, increases the response rate compared with
fluoropyrimidine monotherapy, and has become the stan-
dard first-line therapy for this disease. Bevacizumab (BEV)
and anti-epidermal growth factor receptor (EGFR) mono-
clonal antibodies have also added survival benefits to chemo-
therapy alone; the latter is specifically useful in patients
whose tumors are RAS wild-type. Currently, the median
survival of patients with metastatic colorectal cancer (mCRC)
can reach 30 months (4). However, the clinical benefits of
various treatments are established in clinical trials that enroll
highly selected patients with good performance status (PS),
which is often measured using the Eastern Cooperative Oncology
Group (ECOG) classification. Most patients included in mCRC
trials present with ECOG PS 0-1, and only a minimal per-
centage of those with poor ECOG PS are enrolled. Therefore,
there are scarce data to evaluate whether the benefits
observed in clinical trials also apply to patients with poor PS.
For example, in the landmark FOCUS trial, less than 10% of
patients had ECOG PS 2 (5).
Given the lack of robust evidence to guide treatment
decisions for mCRC patients with poor ECOG PS, an indi-
vidual patient data meta-analysis of randomized trials evalu-
ated the outcomes of systemic chemotherapy in patients with
ECOG PS 2, which represented 8% of the total sample (6).
Patients with ECOG PS 2 experienced a doubled risk ofDOI: 10.6061/clinics/2018/e542s
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grade 3/4 treatment-related toxicities and significantly worse
outcomes, such as 60-day mortality rate (12% vs. 2.8%), lower
response rates (43.8% vs. 32.0%), shorter median PFS (7.6 vs.
4.9 months) and shorter median OS (17.3 vs. 8.5 months) than
those with ECOG PS 0-1. However, patients with even worse
clinical conditions, such as those with ECOG PS 3-4 have not
been represented at all in clinical trials. The results from a
retrospective study performed by our group suggested that
palliative chemotherapy might benefit mCRC patients with
ECOG PS 3-4, as they experienced a low rate of serious
adverse events and lived longer than those treated with BSC
exclusively (7). However, those findings may reflect selection
bias.
Therefore, we have performed a systematic review to
assess the evidence for the treatment of mCRC patients with
ECOG PS X2.
’ MATERIALS AND METHODS
This was a systematic review of studies that evaluated the
treatment outcomes of mCRC patients with poor ECOG/PS
X2. Eligible publications were clinical trials, prospective or retro-
spective cohort studies, case-control studies, case reports or
population-based studies and pooled analyses. We excluded
editorials, commentaries, convention abstracts, literature reviews
and articles written in other languages other than English,
Portuguese or Spanish.
The PubMed, Embase, Cochrane Library and LILACS
databases were searched using the following search terms:
(1) ("Colorectal Neoplasms" [Mesh]) AND ((performance
[Title] AND status[Title]) OR ECOG[Title]) in PubMed;
(2) (’colorectal cancer’/exp OR ’colorectal neoplasms’) AND
(’chemotherapy’/exp OR chemotherapy) AND ’poor per-
formance’ in Embase (ScienceDirect); (3) (tw:("colorectal
cancer")) AND (tw:("poor performance")) AND (tw:(chemo-
therapy)) in LILACS; and (4) ‘‘colorectal neoplasms’’ in the
Cochrane Library. All searches were conducted from the
inception of each database until October 31st, 2017. Addi-
tionally, the reference lists of all the retrieved articles were
reviewed to identify additional eligible studies. This strategy
was used because, after testing several combinations of key
words, this was the search that retrieved the largest number
of studies.
It was initially planned to have a third researcher inde-
pendently extract the data from the studies. However, after
selecting the eligible studies, the data were very hetero-
geneous, and the number of articles was quite small; thus,
two investigators evaluated each article and discussed the
contents, one investigator extracted the data, and then both
discussed and revised all the data. For each eligible paper,
the investigators collected information about study design,
characteristics of the study population, type of cancer-directed
therapy and percentage of poor PS patients and treatment
outcomes, such as OS and treatment-related adverse events.
’ RESULTS
Our initial search revealed 248 articles including 39 from
PubMed, 95 from EMBASE, 60 from LILACS and 54 from the
Cochrane Library, but only 18 were eligible. The number of
studies evaluated and the sequential selection are presented
in detail in Figure 1.
Of the selected articles, 11 were retrospective studies (61%),
two were case series, two were uncontrolled prospective
Figure 1 - Flow chart of the search strategy and eligible articles.
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trials, two were observational studies and one was an indi-
vidual patient meta-analysis. Table 1 summarizes the char-
acteristics of the included studies.
Below we present the studies according to type of setting
and population, as we tried to group the available evidence
in a didactic form.
Bevacizumab and anti-EGFR monoclonal antibodies
A case series of eight patients, most with ECOG PS 2
and one with ECOG PS 3, suggested that a combination of
FOLFOX plus cetuximab for patients with RAS wild-type
tumors who needed tumor shrinkage to alleviate symptoms
related to extensive metastatic disease had clinical benefits.
Improvement in ECOG PS, reduced jaundice and ascites, pain
relief, resolution of intestinal obstruction and/or objective
radiological response occurred in 75% of patients. Their median
survival was 5.2 months (range, 2.5-14+ months) (8).
A retrospective study including 20.1% mCRC patients
with ECOG PSX 2, showed that patients with poorer PS and
comorbidities were significantly more likely than those with
better PS to have their tumors tested for RAS status at diagnosis
in an attempt to induce tumor response with anti-EGFR
monoclonal antibodies (until 60 days after diagnosis) (9).
On the other hand, poor PS was one of the most common
reasons for patients with KRAS wild-type tumors not to be
treated with anti-EGFR antibodies (10).
Jehn et al. (11) performed a retrospective trial to investigate
the combination of irinotecan plus cetuximab in 497 irinotecan-
pretreated patients with KRAS wild-type tumors, of whom
22.9% had ECOG PS X2. A multivariate analysis evaluating
the prognostic influence of age, PS, gender, age at diagnosis,
primary location of mCRC, Charlson Comorbidity Index and
skin toxicity showed that ECOG PS had a negative impact on
PFS (hazard ratio (HR) = 0.61; 95% confidence interval (CI),
0.41–0.89; P = 0.01).
In a prospective phase II study of the combination of
capecitabine + BEV, in which 62% of a total of 45 mCRC
patients had ECOG X2, the overall median PFS was 6.87
months (95% CI, 5.1-11.5 months), the overall objective response
rate (ORR) was 35%, and the median OS was 12.7 months
(95% CI, 6.9-28.2 months); the most frequent grade 3/4 toxi-
cities were diarrhea, fatigue and hand-foot syndrome (12).
Grande et al. (13) performed a retrospective study involv-
ing older and/or frail patients and showed that of 78% those
who received first-line chemotherapy (31% received isolated
5-FU, 29% received oxaliplatin-based treatment, 35% received
an irinotecan-based regimen, and 5% received other chemo-
therapy regimens), 14.6% presented with ECOG PS X2.
Among them, those treated with chemotherapy experienced
a longer 2-year OS rate (12.8% vs. 8.1%, P o 0.0001) than
those treated with supportive care alone.
First-line chemotherapy
A pooled analysis of nine clinical trials (including various
chemotherapy regimens) with a total of 6,286 mCRC patients
treated with first-line chemotherapy was performed of a
subgroup of 509 (8%) patients with ECOG PS X2. For this
subset, the analysis demonstrated that polychemotherapy
led to improved outcomes compared with those of mono-
therapy in terms of PFS (HR = 0.78 for combination vs.
monotherapy; 95% CI, 0.62 to 0.98; P = 0.0001), OS (HR =
0.79; 95% CI, 0.62 to 0.99; P = 0.04) and increased the
likelihood of objective response (odds ratio (OR) = 2.85; 95%
CI, 1.61 to 5.02; P = 0.0003). Patients with poor PS experi-
enced lower response rates (OR = 0.61; P = 0.0001; 43.8% vs.
32%), shorter median PFS (HR = 1.52; P = 0.0001; median
PFS, 7.6 vs. 4.9 months), and poorer OS (HR = 2.18; P =
0.0001; median OS, 17.3 vs. 8.5 months) than those with
ECOG PS 0-1 and had an increased risk of grade 3 and 4
toxicities, particularly nausea (8.5% vs. 16.4%, P = 0.0001)
and vomiting (7.6% vs. 11.9%, P = 0.006). Patients with
ECOG PS 3-4 were not represented (6).
In a retrospective analysis of gastrointestinal cancer patients
with poor PS (32 [27%] were mCRC patients) treated with
different chemotherapy regimens, Shitara et al. (14) showed
that the proportion of patients who experienced treatment-
related mortality was low (0.8%). Despite their deteriorated
health conditions, 10 (31.2%) mCRC patients had radio-
logical and/or biochemical response (decrease in carcino-
embryonic antigen (CEA) or carbohydrate antigen 19-9 (Ca19.9)
levels X 25% of baseline levels after 4 weeks of treatment)
and/or clinical benefit defined by improvement in ECOG PS.
For all responders (N = 78), they found a survival benefit
compared with patients without tumor response (median
OS, 6 vs. 2.2 months, P o 0.001).
Crosara et al. (7) performed a retrospective study of 140
patients with ECOG PS X 2 (58.3% of the total sample) and
found a median OS of 18.4 months for patients with ECOG
PS 0-1, 10.8 months for those with ECOG PS 2 and 6.8 months
for those with ECOG PS 3-4; all patients were treated
with first-line oxaliplatin and/or 5-FU regimens. Although
the findings were not statistically significant, this study still
suggested that patients with ECOG PS 3-4 treated with
chemotherapy presented prolonged median OS compared
with those treated with BSC alone (6.8 vs. 2.3 months, res-
pectively). They did not find differences in term of toxicities
between the ECOG PS 3-4 group treated with chemother-
apy vs. those who received BSC exclusively, but 40% of
patients with ECOG PS 3-4 initially received dose-reduced
chemotherapy.
A prospective observational trial analyzed the outcomes of
mCRC patients who were included in clinical trials vs. those
who were not, and 17% of the patients who were not
included in clinical trials had poor PS. Of all patients, 36%
were included in a clinical trial, and 32% received BSC alone;
the most common reason for this treatment option was poor
PS in 54% of patients, the presence of comorbidities in 14%,
declination of treatment in 13%, very old age in 13% and
other causes in 6%. Clinical trial patients presented pro-
longed OS (21.3 months) compared with patients treated
with combination chemotherapy outside of a clinical trial
(OS = 15.2 months) (15).
In a multivariate analysis performed as part of a retro-
spective study by Massacesi et al. (16), ECOG PS X 2 (8.1%
of the sample) was associated with short-term survival
(defined as p 6 months) and initial progression after first-
line 5-FU-based chemotherapy regimens (OR = 3.42; 95% CI,
1.48-7.89; P = 0.015.
Second- and subsequent-line therapy
Sørbye et al. (17) followed 112 patients after initial treat-
ment with oxaliplatin-based regimens and observed that 47%
of them did not receive second-line treatment with irinotecan-
based chemotherapy. The main cause of this lack of second-
line treatment was poor PS as defined by ECOG PS 2-4 in
59% of patients, which led to a median OS after first-line
progression of 1.7 months.
4
Poor performance mCRC treatment
da Silva Rocha LS and Riechelmann RP
CLINICS 2018;73(suppl 1):e542s
In a retrospective trial involving 140 mCRC patients with
ECOG X2 conducted by our group, thirty-seven (35%)
received subsequent lines of chemotherapy, mostly based
on irinotecan and fluoropyrimidine, suggesting that some
patients derived sufficient benefit from first-line chemother-
apy to be well enough to receive subsequent lines of treat-
ment. Unfortunately, we were unable to evaluate the benefits
of targeted anti-EGFR agents, which are reserved as a third-
line treatment as per institutional protocol, because few
patients with ECOG PS 3-4 lived long enough to receive
third-line treatment (7).
A prospective trial conducted in two Spanish centers included
patients with poor PS and tumors that were primarily resis-
tant to 5-FU who received weekly second-line irinotecan.
Considering the 26 mCRC patients with ECOG PS X 2
(76.5% of the sample), 20.6% (95% CI, 6.3-34.9%) experienced
tumor response, and 38.2% of patients had stable disease.
The median OS was 8.3 months (95% CI, 1.7-1.69), and the
most frequent grade 3/4 toxicities were neutropenia in 11
patients (32.4%) and diarrhea in 10 patients (29.4%) (18).
In another retrospective study of 25 patients, 8% had
ECOG PS X 2. Investigators evaluated the efficacy of IROX
(irinotecan + oxaliplatin) in pretreated mCRC patients
(median of 3 previous treatments [range, 2 to 7]), demon-
strating an overall median OS of 7 months (95% CI, 6.2-7.8
months) and a disease control rate of 32%, without dif-
ferentiating between patients with good vs. poor PS (19).
A case series including 4 patients (25%) with ECOG PS X
2 treated with second-line irinotecan monotherapy demon-
strated an overall partial response in 20% of patients and
stable disease in 46.6%; 25% died within 30 days of begin-
ning treatment (20).
Hospitalized patients
In a retrospective trial of 199 inpatients with advanced
incurable cancers of whom 18 (9%) had mCRC, palliative
chemotherapy was administered in all the included patients,
and 77% had improved symptoms and were discharged
from hospital; 72% even received further chemotherapy, but
their median survival was 4.5 months. This study did not
present the results separately for mCRC patients (21).
’ DISCUSSION
Even though some patients with mCRC present with a
deteriorated PS in clinical practice, the best treatment for
these patients remains unknown. In a previous retrospective
study performed by our group, 27% of mCRC patients treated
in a large public cancer center had ECOG PS 3-4 at the time
the first-line treatment decision was made (7). Here, we
present our findings of a systematic review of the litera-
ture to answer the pragmatic clinical question of how to treat
these patients with poor PS. Despite the relevance of this
topic, only a few studies, with most being retrospective
cohort studies or case series, have evaluated the treatment
outcomes of mCRC patients with poor ECOG PS. However,
some studies have suggested treatment-associated benefits,
such as radiological and/or symptomatic improvement,
prolonged OS and low risk of grade 3/4 toxicities with
dose-reduced therapies.
In 2012, the American Society of Clinical Oncology pub-
lished their top five recommendations to improve cancer care
and reduce costs, the first being ‘‘Do not use cancer-directed
therapy for patients with solid tumors who have the following
characteristics: low performance status (3 or 4), no benefit from
prior evidence-based interventions, not eligible for a clinical
trial, and with no strong evidence supporting the clinical
value of further anticancer treatment’’ (22). However, we
think the ECOG PS is a somewhat unrefined classification as
it does not reflect the subtle aspects of clinical evaluation. For
example, some patients without (or with a few) comorbid
illnesses may have ECOG PS 3 or 4 that is exclusively
induced by metastatic disease. In this scenario, tumor shrink-
age may improve symptoms, for example, in patients with
extensive bone metastases and/or medullary compression
from a chemosensitive tumor. In this situation, oncologists
must decide to either follow the evidence and/or expert
guidelines that recommend BSC alone or risk treating patients
without knowing the likelihood of treatment benefits. Addi-
tionally, patients may have poor PS due to chronic physical
limitations or disabilities that do not necessarily pose risks to
clinical trial participation, such as stable neurological sequelae
from polio or stroke. Certainly, the treatment outcomes vary
considerably in patients who are frail due oncologic disease
vs. those who are frail because of comorbidities, severe organ
dysfunction or advanced age, even though all these clinical
conditions imply poor ECOG PS. Indeed, some studies
included in this systematic review reported tumor shrinkage
and even improvement in cancer-associated symptoms with
standard chemotherapy. Therefore, we strongly advocate
that the ECOG PS scale alone should not be used exclusively
to guide treatment decisions. In these situations, other scales
can help to make treatment decisions, such as the Edmonton
Symptom Assessment System (ESAS) (23), which sum-
marizes symptom burden, the Palliative Performance Scale
(24), the prognostic Charlson Comorbidity Index (25), and
scales that predict the probability of severe toxicities due to
chemotherapy. (21,26) Last but not least, clinical judgment
should prevail when the scientific evidence is lacking.
Even though combination chemotherapy improves response
rates and, in some cases, disease-related symptoms com-
pared with monochemotherapy in mCRC patients, those
with poor PS have not been included in trials evaluating the
combination of fluoropyrimidine with either oxaliplatin or
irinotecan (27-31), and patients with ECOG PS X 3 are
systematically excluded from the main second- and third-
line trials for CRC treatment (19,32-39). We have data from
patients with good PS that shows that de-escalation of chemo-
therapy (40) or even complete cessation of chemotherapy
does not compromise OS, while it preserves quality of
ife (41). Additionally, the safety and benefits from adding
BEV or anti-EGFR agents to standard chemotherapy in
patients with poor ECOG PS are unknown because few
patients with ECOG PS 2 and none with an ECOG PS 3-4
have been enrolled in phase III trials with these anticancer
agents. Due to the paucity of evidence-based information
to guide treatments for patients with poor PS, community
oncologists make decisions based on clinical experience or
intuition. Although reduction in dose intensity of treatment
is a common alternative in clinical practice when dealing
with frail patients, there are no data to demonstrate that
reduced doses provide the same benefit as full dose regi-
mens. Some authors have suggested that in the frailest
patients, a lower dose of chemotherapy should be con-
sidered for the first cycle, and if this is well tolerated, a
subsequent dose escalation may be tested (12). In our
institutional retrospective study, patients with poor PS
did not develop significantly more grade 3/4 toxicities
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probably because most of them were managed with initial
dose reduction (7).
Additionally, because only 2-4% of patients with meta-
static neoplasia are enrolled in clinical trials, which is much
lower than the recommended rate of 10-15% (15), the over-
whelming scientific evidence does not reflect the realities
experienced by community oncologists. In that sense, trials
that include relevant subsets of the cancer population must
be conducted, e.g., trials including patients with poor PS,
elderly, HIV-positive individuals, and those with chronic
kidney disease. In developing countries and in poor popu-
lations, the external validity of clinical trials may be even more
problematic because late diagnosis and precarious access to a
healthcare system often leads to patients presenting with more
advanced disease, ultimately culminating in more patients with
compromised PS at the time of presentation.
Forty percent of elderly patients with newly diagnosed
colorectal cancer present with poor PS due to cancer compli-
cations or comorbidities (42). Consequently, data from studies
with elderly patients are often extrapolated to nonelderly
frail patients (ECOG PS X 2) (12). Several studies involv-
ing elderly mCRC patients have demonstrated that fluoro-
pyrimidine (5-FU or capecitabine) used in isolation or in
combination with BEV provides prolonged median PFS,
encouraging response rates and acceptable toxicities (12,43,44).
While these findings provide the rationale for treating fragile
patients with ‘‘more gentle’’ regimens, they should not be used
alone to guide therapy in mCRC patients with poor ECOG PS.
Another important aspect that should be considered when
deciding treatment strategies for mCRC patients with poor
PS is the efficacy of the available therapies. While there is the
generally accepted concept that performing chemotherapy
during the last 30 days of a patient’s life is not a good clinical
practice (45), tumor subtype and chemosensitivity certainly
influence patient outcomes and the indications for treatment.
For example, a retrospective study showed that inpatients
with clinical stage III ovarian cancer treated with platinum-
based chemotherapy achieved median survival of 21 months
(46). Additionally, with the modernization of cancer thera-
pies and new drugs that lead to high response and low toxi-
city rates, oncologists should better evaluate the risk-benefit
ratio of treating patients with poor PS, such as those whose
tumors have DNA mismatch repair-deficient (dMMR)/
microsatellite instability-high (MSI-H) and are very likely to
benefit from immunotherapy (47,48).
A major limitation of the ability our systematic review
to reach a conclusion on this topic was the small number
of studies included and their limited quality. Additionally,
because poor PS is sometimes evaluated as a secondary or
even exploratory endpoints, we may have missed some
studies in our search. Searching for Portuguese, English and
Spanish articles may have led us to miss data from studies
from developing countries where patients have limited
access to healthcare and probably a high number of fragile
patients are treated. Nevertheless, given the clear lack of
research on mCRC patients with poor PS, we do not think
that the inclusion of any unintentionally missed studies
would have changed the overall picture of our systematic
review.
In this systematic review we show that there are very few
studies involving mCRC patients with poor PS, principally
those with ECOG PS 3-4, which implies that these patients
are systematically excluded from clinical trials. While some
studies have suggested benefits in terms of symptomatic
responses with standard chemotherapy, a true survival gain
could not be demonstrated. Larger prospective epidemiolo-
gical database studies are needed to elucidate whether and
which patients with poor PS can benefit from treatment with
palliative chemotherapy or from new targeted therapies and
immunotherapy. Regarding clinical trials, we advocate that
more flexible eligibility criteria be used and at least a limited
number of patients with poor PS, especially those with poor
ECOG PS and good organ function but with symptomatic
burden, be included. Following the same logic, studies should
separately analyze impaired PS due to active comorbidities, the
sequelae of previous but stable disease and organ failure due to
oncological disease.
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